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Clinical features and outcomes of COVID-19 in 
patients with rheumatic diseases treated with 
biological and synthetic targeted therapies
From the beginning of the COVID-19 pandemic, more than 
4.7 million cases have been detected in the world, Spain being 
one of the countries hardest hit by the SARS- CoV-2.1 The role 
of the immune system and immunomodulatory therapies in the 
evolution of this infection is still controversial.2 The study of 
patients with rheumatic and musculoskeletal diseases (RMDs) 
such as rheumatoid arthritis (RA), spondyloarthropathies (SpA) or 
systemic lupus erythematosus, treated with immunomodulatory 
therapies is essential to understand the prognosis of COVID-19 in 
this specific population and to the management of these patients.
BIOBADASER is a multicentre prospective observational registry 
promoted by the Spanish Society of Rheumatology (SER) and 
supported by the Spanish Agency of Drugs and Medical Devices. 
It is aimed at assessing safety in patients with RMDs starting treat-
ment with any biological (bDMARD) or targeted synthetic disease- 
modifying antirheumatic drug (tsDMARD). More than 6600 
patients are prospectively followed up in BIOBADASER 3.0.
This report describes the clinical characteristics and outcomes 
of patients with COVID-19 in BIOBADASER. We have identified 
41 patients with RMDs treated with bDMARD and tsDMARD 
diagnosed of COVID-19 at 15 hospitals in the registry. Thirty- one 
patients were diagnosed because positive PCR test for SARS- CoV-2, 
and 10 patients because a highly compatible clinical picture and 
close contact with confirmed positive cases. Table 1 shows baseline 
characteristics of the patients. Twenty- five (61.0%) patients were 
female and 16 (39,0%) male, with a mean age of 59.4 years. They 
had long- standing (12.8 years) refractory (three previous bDMARD/
tsDMARDs) diseases with 5.7 years of bDMARD/tsDMARD therapy 
duration. Twenty- one patients (51.2%) had RA. Comorbidities 
included hypertension (36.6%), past or current smoker (36.8%), 
diabetes (9.8%) and high body mass index (BMI) (27.7 (5.6) kg/m2—
mean (SD)). Eighteen patients (43.9%) were using TNF inhibitors, 
seven JAK inhibitors (17.1%, 9.8% baricitinib and 7.3% tofacitinib) 
and five (12.2%) IL-6 inhibitors. Seventeen (41.5%) patients were 
using methotrexate and four (9,8%) hydroxychloroquine.
Three patients died (7.3%); a 63- year- old RA male on anak-
inra—plus prednisone 5 mg/day—(comorbidities: smoker, BMI 
34.6); a 56- year- old SpA female on secukinumab—no glucocor-
ticoids—(past smoker, BMI 28.4) and a 91- year- old vasculitis 
female on rituximab—plus prednisone 5 mg/day—(hyperten-
sion). Hospitalisation was required in 28 patients (68.3%) and 
intensive care unit (ICU) admission in 6. Thirty- five (85.4%) 
patients are fully recovered at the moment of this analysis, and 
three patients are still hospitalised, none in ICU.
Data on COVID-19 in patients with RMDs is still scarce.3–6 
Because of the rapid evolution of the pandemic, it is important 
to accrue information on the clinical course of rheumatic 
patients on bDMARD/tsDMARDs developing COVID-19. The 
reduced number of patients in our study limits the possibility 
of drawing solid conclusions. However, these findings point in 
the direction that COVID-19 course and mortality in patients 
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Table 1 Clinical features and treatments in patients with rheumatic diseases on targeted therapies with the diagnosis of COVID-19
Variable RA SpA Other rheumatic diseases Total
N 21 12 8 41
Age at COVID-19 onset, years (SD) 61.3 (13.9) 57.1 (11.5) 57.1 (23.9) 59.4 (15.6)
Sex, female, n (%) 14 (66.6) 5 (41.7) 6 (75.0) 25 (61.0)
Disease duration (time since rheumatic diagnosis to COVID-19), years (SD) 12.0 (8.3) 15.0 (14.2) 11.4 (7.9) 12.8 (9.8)
Time with bDMARDs/tsDMARDs (time since beginning of treatment to COVID-19), years (SD) 5.8 (5.2) 5.3 (5.8) 5.7 (9.6) 5.7 (5.7)
Comorbidities and risk factors
Charlson index, mean (SD) 2.5 (1.6) 2.3 (1.7) 3.4 (3.1) 2.6 (2.0)
BMI, mean (SD) 27.9 (5.1) 29.4 (4.7) 25.2 (7.5) 27.7 (5.6)
Hypertension, n (%) 6 (28.6) 5 (41.7) 4 (50.0) 15 (36.6)
Smoking status, n (%)
  Never smoker 14 (66.7) 8 (66.7) 5 (62.5) 27 (65.8)
  Current smoker 2 (9.5) 0 (0.0) 2 (25.0) 4 (9.8)
  Former smoker 5 (23.8) 4 (33.3) 1 (12.5) 10 (24.4)
COVID-19 diagnosis, evolution and outcome
COVID-19 diagnosis, n (%)
  Confirmed cases (positive PCR test) 16 (76.2) 8 (66.7) 7 (87.5) 31 (75.6)
  Suspicious cases (highly compatible clinical picture) 5 (23.8) 4 (33.3) 1 (12.5) 10 (24.4)
  COVID-19 outcome
  Recovered without sequelae 18 (85.7) 11 (91.7) 6 (75.0) 35 (85.4)
  Not yet recovered 2 (9.5) 0 (0.0) 1 (12.5) 3 (7.3)
  Death 1 (4.8) 1 (8.3) 1 (12.5) 3 (7.3)
  Hospitalisation, n (%) 16 (76.2) 8 (66.7) 4 (50.0) 28 (68.3)
  Intensive care unit, n (%) 4 (19.0) 2 (16.7) 0 (0.0) 6 (14.6)
Rheumatic disease: treatment and clinical features
Last DAS-28 available (previous to COVID-19), mean (SD) 3.9 (1.4) 3.3 (1.3) – 3.6 (1.4)
bDMARD/tsDMARDs previous to COVID-19), n (%)
  TNF inhibitors 7 (33.3) 7 (58.3) 4 (50.0) 18 (43.9)
  Anti- IL6 monoclonal antibodies 3 (14.3) 0 (0.0) 2 (25.0) 5 (12.2)
  Anti- CD20 monoclonal antibodies 2 (9.5) 0 (0.0) 1 (12.5) 3 (7.3)
  Anti- IL1 monoclonal antibodies 1 (4.8) 0 (0.0) 0 (0.0) 1 (2.4)
  Anti- IL17A monoclonal antibodies 0 (0.0) 5 (41.7) 0 (0.0) 5 (12.2)
  Abatacept 1 (4.8) 0 (0.0) 1 (12.5) 2 (4.9)
  JAK inhibitors 7 (33.3) 0 (0.0) 0 (0.0) 7 (17.1)
  Baricitinib 4 (9.0) 0 (0.0) 0 (0.0) 4 (9.8)
  Tofacitinib 3 (14.3) 0 (0.0) 0 (0.0) 3 (7.3)
Number of previous bDMARD/tsDMARDs, mean (SD) 4.2 (2.9) 2.0 (1.0) 1.6 (0.7) 3.0 (2.4)
Use of concomitant csDMARDS
  Methotrexate 11 (52.4) 4 (33.3) 2 (25.0) 17 (41.5)
  Hydroxychloroquine 2 (9.5) 0 (0.0) 2 (25.0) 4 (9.8)
  Others 0 (0.0) 2 (16.7) 0 (0.0) 2 (4.9)
  Monotherapy 12 (57.1) 6 (50.0) 4 (50.0) 22 (53.7)
  Use of glucocorticoids, n (%) 13 (61.9) 2 (16.7) 5 (62.5) 20 (83.3)
Dose of glucocorticoids (before COVID-19), mg, mean (SD) 5.5 (3.3) 7.5 (2.1) 6 (2.2) 5.8 (2.9)
Concomitant use of NSAIDs, n (%) 7 (33.3) 3 (25.0) 0 (0.0) 10 (24.4)
bDMARDs, biological disease- modifying antirheumatic drugs; BMI, body mass index; n, number of patients; NSAIDs, non- steroidal anti- inflammatory drugs; RA, rheumatoid arthritis; SpA, spondyloarthropathies; tsDMARDs, targeted synthetic 
disease- modifying antirheumatic drugs.
with RMDs treated with b/tsDMARD do not differ from the 
general population (12.0% mortality rate and hospitalisation 
rate 53.6% by COVID-19 in Spain1). Of interest, these high 
mortality and hospitalisation rates are likely due to a diag-
nostic bias with PCR testing reserved for the most symptomatic 
patients, as suggested by a recent (unpublished) report by the 
Spanish Ministry of Health showing a prevalence of IgG sero-
conversion to SARS- Cov-2 of 5% in Spain. That is 10 times 
greater than the PCR confirmed cases (1). The present data, in 
addition to previous publications, is crucial to clarify the risks of 
patients with rheumatic diseases and their immunosuppressive 
medications. Doubtlessness, additional studies are still needed. 
To this end, the SER is prospectively collecting information on 
COVID-19 in three registries (BIOBADASER, RELESSER and 
CARMA) in more than 9000 patients with rheumatic diseases.
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